Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
Eur Urol. 2015 Dec;68(6):1045-53. doi: 10.1016/j.eururo.2015.01.013. Epub 2015 Feb 2.
Detection of clinically significant prostate cancer (PCa) is a major challenge. It has been shown that multiparametric magnetic resonance imaging (mpMRI) facilitates localisation of PCa and can help in targeting prostate biopsy.
To systematically review the literature to determine the diagnostic accuracy of mpMRI in the detection of clinically significant PCa.
The Pubmed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) databases were searched from January 1, 2000 to September 30, 2014, using the search criteria "prostate OR Pca OR PSA OR prostatic OR prostate cancer" AND "MR OR NMR OR NMRI OR MRI OR magnetic resonance OR ADC OR DWI OR DCE OR diffusion weighted OR dynamic contrast OR multiparametric OR MRSI OR MR spectroscopy". Two reviewers independently assessed 1729 records. Two independent reviewers assessed the methodologic quality using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) 2 tool.
Twelve articles were eventually selected. Patients had a median age of 62-65 yr (range 39-83 yr), a median prostate-specific antigen (PSA) level of 5.1-13.4 ng/ml (range 1.2-228 ng/ml), and Gleason score of 6-10. Various definitions of clinical significance were used, mainly based on maximum cancer core length and grade at biopsy, number of positive cores, and PSA. Detection of clinically significant PCa using mpMRI ranged from 44% to 87% in biopsy-naïve males and men with prior negative biopsies using prostate biopsy or definitive pathology of a radical prostatectomy specimen as the reference standard. The negative predictive value for exclusion of significant disease ranged from 63% to 98%.
mpMRI is able to detect significant PCa in biopsy-naïve males and men with prior negative biopsies. The negative predictive value of mpMRI is important to the clinician because mpMRI could be used to rule out significant disease. This may result in fewer or no systematic or targeted biopsies in patients with PSA suspicious for prostate cancer.
We reviewed the diagnostic accuracy of multiparametric magnetic resonance imaging (mpMRI) for the detection of clinically significant prostate cancer (PCa). We conclude that mpMRI is able to detect significant PCa and may used to target prostate biopsies.
检测临床上显著的前列腺癌(PCa)是一项主要挑战。已经表明,多参数磁共振成像(mpMRI)有助于 PCa 的定位,并有助于靶向前列腺活检。
系统地综述文献,以确定 mpMRI 在检测临床上显著的 PCa 中的诊断准确性。
从 2000 年 1 月 1 日至 2014 年 9 月 30 日,使用“前列腺或前列腺癌或 PSA 或前列腺或前列腺癌”和“MR 或 NMR 或 NMRI 或 MRI 或磁共振或 ADC 或 DWI 或 DCE 或扩散加权或动态对比或多参数或 MRSI 或磁共振波谱”的搜索标准,在 Pubmed、Embase 和 Cochrane 对照试验中心注册库(CENTRAL)数据库中进行检索。两位评审员独立评估了 1729 条记录。两位独立评审员使用诊断准确性研究的质量评估(QUADAS-2)2 工具评估方法学质量。
最终选择了 12 篇文章。患者的中位年龄为 62-65 岁(范围 39-83 岁),中位前列腺特异性抗原(PSA)水平为 5.1-13.4ng/ml(范围 1.2-228ng/ml),Gleason 评分为 6-10。使用了各种临床意义的定义,主要基于活检中最大癌核长度和分级、阳性核数和 PSA。使用 mpMRI 在初次活检和初次活检阴性的男性中检测临床上显著的 PCa,其范围为 44%至 87%,以前列腺活检或根治性前列腺切除术标本的明确病理学作为参考标准。阴性预测值可排除显著疾病的范围为 63%至 98%。
mpMRI 能够在初次活检和初次活检阴性的男性中检测出显著的 PCa。mpMRI 的阴性预测值对临床医生很重要,因为 mpMRI 可用于排除显著疾病。这可能导致 PSA 怀疑前列腺癌的患者进行的系统或靶向活检更少或没有。
我们综述了多参数磁共振成像(mpMRI)检测临床上显著前列腺癌(PCa)的诊断准确性。我们得出结论,mpMRI 能够检测出显著的 PCa,并可用于靶向前列腺活检。